ARCHIVES

NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.

This article is from The Cancer Letter archive.

Vol. 29 No. 46 | December 12, 2003

Download PDF Visit The Full Archive

Related Articles

FDA Approves Lymphoseek For Imaging Lymph Nodes

March 29, 2013

Grantees Not In Danger Of Losing Cost-Free Biological Materials, But Can’t Have Chemicals

September 9, 1977

Gregory Reaman Named Associate Director of FDA Office of Oncology Drug Products

June 3, 2011

Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study

December 31, 2010

Funding opportunities listed.

October 29, 2004

DeVita: No Decision Yet On FCRF Award

July 17, 1987